Half-life

0.5 h

Tmax

0.25 h

Category

peptide

Also known as: tetra-substituted-grf, mod-grf-1-29, mod-grf-no-dac, modified-grf-1-29

CJC-1295 without the drug affinity complex (DAC) is a tetra-substituted analogue of growth-hormone-releasing hormone (GHRH) designed to resist dipeptidyl peptidase IV (DPP-IV) cleavage. It retains full GHRH receptor agonism but has a very short plasma half-life of approximately 30 minutes, requiring frequent dosing or co-administration with a longer-lived GH secretagogue. Without the DAC extension, this form is also known as Mod GRF 1-29 and is the more common variant in research settings. Users should log dose timing, GH-related effects, and injection site responses to assess protocol effectiveness.

Mechanism

A GHRH analog that stimulates the GHRH receptor to promote pulsatile growth-hormone release. Variants differ by the presence of a drug-affinity complex (DAC) that extends duration of action.

Research summary

Studied as a long-acting GHRH analog in early clinical pharmacology work. It is not an FDA-approved therapeutic, and long-term human outcome data are limited.

Reported side effects

Reported effects include injection-site reactions, flushing, and headache. Sustained elevation of growth hormone and IGF-1 is a monitoring consideration in a clinical context. The full profile is not established.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

Prolonged stimulation of GH and IGF-I secretion by CJC-1295 · Teichman et al., J Clin Endocrinol Metab (2006)Describes CJC-1295 with DAC. The no-DAC form (Mod GRF 1-29) has a plasma half-life of roughly 30 minutes; no separate human PK paper was identified.

References

CJC-1295 PK studyDOI: 10.1210/jc.2005-1536

TrackPep adalah aplikasi pencatatan. Aplikasi ini merekam apa yang Anda catat dan tidak pernah merekomendasikan atau menghitung jumlahnya.